MONTREAL, QUEBEC--(Marketwire - September 21, 2009) - Theratechnologies (TSX: TH) announced today that Yves Rosconi, President and Chief Executive Officer, will present an overview of the Company, on Wednesday, September 23, at 12:30 p.m., at the 2009 UBS Global Life Sciences Conference which will take place at the Grand Hyatt in New York City. At this occasion, Mr. Rosconi will discuss how the Company is well positioned with a business plan built on an advanced compound and a solid balance sheet making Theratechnologies a leader in the Canadian biotech industry.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company with core expertise in peptide-based therapeutics. Its most advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.
In late 2008, Theratechnologies completed its Phase 3 clinical program which was designed to evaluate tesamorelin in treating excess abdominal fat in HIV patients with lipodystrophy. The Company also signed a collaboration and licensing agreement with EMD Serono, Inc., for the commercialization of tesamorelin in the United States.
With a New Drug Application recently filed with the US authorities, Theratechnologies’ growth strategy is firmly focused on the development of tesamorelin in the United States and in other potential lipodystrophy markets, as well as through additional clinical programs for other medical conditions.
Contacts:
Theratechnologies Inc.
Andrea Gilpin
Vice president, IR & Communications
514-336-7800, ext. 205
communications@theratech.com
